Atrial natriuretic peptide alleviates cardiovascular and metabolic disorders in a rat endotoxemia model: A possible role for its anti-inflammatory properties

Journal of Nippon Medical School

Volumn 77, Issue 6, 2010, Pages 296-305

  Mori, Masaki ^a   Yamanashi, Yoshitaka ^a   Kobayashi, Katsuya ^a   Sakamoto, Atsuhiro ^a  

^a NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial natriuretic peptide; Lipopolysaccharide; Nitric oxide synthase 2; Real time reverse transcriptase polymerase chain reaction; Tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; ATRIAL NATRIURETIC FACTOR ALPHA; BACTERIUM LIPOPOLYSACCHARIDE; BICARBONATE; CARBON DIOXIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; HEME OXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LACTIC ACID; MESSENGER RNA; OXYGEN; TUMOR NECROSIS FACTOR ALPHA;

ACID BASE BALANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD GAS ANALYSIS; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTOXEMIA; ESCHERICHIA COLI; GENE EXPRESSION; HEART LEFT VENTRICLE; MALE; MEAN ARTERIAL PRESSURE; METABOLIC DISORDER; NONHUMAN; PULSE RATE; RAT;

EID: 78650083746     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.77.296     Document Type: Article

References (25)

1. Court O, Kumar A, Parrillo JE: Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002; 6: 500-508. (Pubitemid 35414581)
2. Peng T, Shen E, Fan J, Zhang Y, Arnold JM, Feng Q: Disruption of phospholipase Cgamma1 signalling attenuates cardiac tumor necrosis factor-alpha expression and improves myocardial function during endotoxemia. Cardiovasc Res 2008; 78: 90-97. (Pubitemid 351430950)
3. Merx MW, Weber C: Sepsis and the heart. Circulation 2007; 116: 793-802.
4. Rudiger A, Singer M: Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35: 1599-1608.
5. Khalil AA, Hall JC, Aziz FA, Price P: Tumour necrosis factor: implications for surgical patients. ANZ J Surg 2006; 76: 1010-1016. (Pubitemid 44581492)
6. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-595.
7. Hashimoto M, Ito T, Fukumitsu H, Nomoto H, Furukawa Y, Furukawa S: Stimulation of production of glial cell line-derived neurotrophic factor and nitric oxide by lipopolysaccharide with different dose-responsiveness in cultured rat macrophages. Biomed Res 2005; 26: 223-229.
8. Li H, Wallerath T, Forstermann U: Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide 2002; 7: 132-147. (Pubitemid 35177005)
9. Abraham NG, Kappas A: Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79-127. (Pubitemid 351439218)
10. Takahashi T, Morita K, Akagi R, Sassa S: Heme oxygenase-1: a novel therapeutic target in oxidative tissue injuries. Curr Med Chem 2004; 11: 1545-1561. (Pubitemid 38735796)
11. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K: Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 2005; 69: 283-290.
12. Furst R, Bubik MF, Bihari P, et al.: Atrial natriuretic peptide protects against histamine-induced endothelial barrier dysfunction in vivo. Mol Pharmacol 2008; 74: 1-8. (Pubitemid 351872153)
13. Nishikimi T, Maeda N, Matsuoka H: The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006; 69: 318-328.
14. Ladetzki-Baehs K, Keller M, Kiemer AK, et al.: Atrial natriuretic peptide, a regulator of nuclear factor-kappaB activation in vivo. Endocrinology 2007; 148: 332-336. (Pubitemid 46021466)
15. Vollmar AM: The role of atrial natriuretic peptide in the immune system. Peptides 2005; 26: 1086-1094.
16. Kiemer AK, Vollmar AM: The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 2001; 60 Suppl 3: iii68-70.
17. Sakamoto A, Matsumura J, Mii S, Gotoh Y, Ogawa R: A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production. Shock 2004; 22: 76-81. (Pubitemid 40228214)
18. Takemori K, Kobayashi K, Sakamoto A: Expression of pulmonary vasoactive factors after sevoflurane anaesthesia in rats: a quantitative real-time polymerase chain reaction study. Br J Anaesth 2008; 100: 190-194. (Pubitemid 351773671)
19. Tsukagoshi H, Shimizu Y, Kawata T, et al.: Atrial natriuretic peptide inhibits tumor necrosis facto-ralpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept 2001; 99: 21-29. (Pubitemid 32232124)
20. Kiemer AK, Bildner N, Weber NC, Vollmar AM: Characterization of heme oxygenase 1 (heat shock protein 32) induction by atrial natriuretic peptide in human endothelial cells. Endocrinology 2003; 144: 802-812. (Pubitemid 36262847)
21. Foresti R, Clark JE, Green CJ, Motterlini R: Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. J Biol Chem 1997; 272: 18411-18417. (Pubitemid 27306435)
22. Datta PK, Lianos EA: Nitric oxide induces heme oxygenase-1 gene expression in mesangial cells. Kidney Int 1999; 55: 1734-1739. (Pubitemid 29197960)
23. Szabo C, Mitchell JA, Thiemermann C, Vane JR: Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 1993; 108: 786-792. (Pubitemid 23067954)
24. Malyshev E, Tazi KA, Moreau R, Lebrec D: Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. J Gastroenterol Hepatol 2007; 22: 2195-2201. (Pubitemid 350145595)
25. Reinhart K, Karzai W: Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121-125.